Alzheimer’s disease (AD) progression varies based on the presence of tau and amyloid-beta (Aβ) proteins in the brain. Patients with high levels of both tau and Aβ experience rapid memory decline, while those with high Aβ but low tau show a slower progression. The research emphasizes that tau levels are crucial for diagnosing and managing AD effectively. This insight could lead to more personalized treatment strategies as biomarker technology advances.
You May Also Like
Are Smokers Really Less Likely to Develop Parkinson’s?
September 8, 2024
Upper GI Damage Linked to 76% Higher Parkinson’s Disease Risk
September 7, 2024
Nighttime Light Pollution Linked to Higher Alzheimer’s Risk
September 6, 2024
More From Author
Complex needs shelter wins praise from Regina police, addiction experts
September 15, 2024
Victoria police chief wants more powers for hospital security
September 14, 2024
+ There are no comments
Add yours